Preparation and Cytotoxic Evaluation of PGV-1 Derivative, CCA-1.1, as a New Curcumin Analog with Improved-Physicochemical and Pharmacological Properties

Rohmad Yudi Utomo ^1,2 , Febri Wulandari ¹ , Dhania Novitasari ¹ , Beni Lestari ¹ , Ratna Asmah Susidarti ^1,2 , Riris Istighfari Jenie ^1,3 , Jun-ya Kato ⁴, Sardjiman Sardjiman ² , Edy Meiyanto ^1,3 *

Cited by CrossRef: 4

1- Ardiansah B, Hardhani M, Putera D, Wukirsari T, Cahyana A, Jia J, Khan M. Design, synthesis, and antioxidant evaluation of monocarbonyl curcumin analogues tethered 1,2,3-triazole scaffold. Case Studies in Chemical and Environmental Engineering. 2023;8:100425 [Crossref]

2- Novitasari D, Nakamae I, Yoneda-Kato N, Kato J, Hippo Y, Suenaga Y, Putri D, Meiyanto E, Ikawati M, Ooi D. The Combination of Sorafenib and PGV‐1 Inhibits the Proliferation of Hepatocellular Carcinoma Through c‐Myc Suppression in an Additive Manner: In Vitro Studies. Advances in Pharmacological and Pharmaceutical Sciences. 2024;2024(1) [Crossref]

3- Hermawan A, Wulandari F, Hanif N, Utomo R, Jenie R, Ikawati M, Tafrihani A. Identification of potential targets of the curcumin analog CCA-1.1 for glioblastoma treatment : integrated computational analysis and in vitro study. Sci Rep. 2022;12(1) [Crossref]

4- Wulandari F, Ikawati M, Widyarini S, Kirihata M, Novitasari D, Kato J, Meiyanto E. Tumour‐suppressive effects of curcumin analogs CCA‐1.1 and Pentagamavunone‐1 in colon cancer: In viv o and in vitro studies. 2023;14(4):317 [Crossref]

5- Novitasari D, Jenie R, Kato J, Meiyanto E. Chemoprevention curcumin analog 1.1 promotes metaphase arrest and enhances intracellular reactive oxygen species levels on TNBC MDA-MB-231 and HER2-positive HCC1954 cells. 2023;18(4):358 [Crossref]